Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy-Reference-Cited by-同舟云学术

Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy

Published:2018-01-04 Issue:1 Volume:131 Page:121-130
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Hill Joshua A.¹²,Li Daniel³,Hay Kevin A.⁴⁵,Green Margaret L.¹²,Cherian Sindhu⁶,Chen Xueyan⁶,Riddell Stanley R.¹⁴,Maloney David G.¹⁴,Boeckh Michael¹²,Turtle Cameron J.¹⁴

Affiliation:

1. Department of Medicine, University of Washington, Seattle, WA;

2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

3. Juno Therapeutics, Seattle, WA;

4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;

5. Department of Medicine, University of British Columbia, Vancouver, BC, Canada; and

6. Department of Laboratory Medicine, University of Washington, Seattle, WA

Abstract

Publisher's Note: There is a Blood Commentary on this article in this issue.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/1/121/1367372/blood793760.pdf

Reference28 articles.

1. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies;Turtle;Clin Pharmacol Ther,2016

2. The promise of chimeric antigen receptor T-cell therapy;Frey;Oncology (Williston Park),2016

3. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse;Kenderian;Biol Blood Marrow Transplant,2017

4. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells;Turtle;Sci Transl Med,2016

5. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients;Turtle;J Clin Invest,2016

Cited by 416 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors;Cytotherapy;2024-09

2. Engineering a solution for allogeneic CAR-T rejection;Molecular Therapy;2024-09

3. Septic shock in the immunocompromised cancer patient: a narrative review;Critical Care;2024-08-30

4. Tracking non-relapse mortality after CAR T cell therapy;Nature Medicine;2024-08-30

5. Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention;Frontiers in Immunology;2024-08-26